Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Bullboard (NDAQ:AXSM)

View:
Post by whytestockson Nov 12, 2024 3:45pm

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

BREAKING NEWS: $AXSM Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript2024-11-12 15:15:17 ET Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q3 2024 Earnings Call Nov 12 ...more  
31
Post by whytestockson Nov 12, 2024 3:15pm

Axsome Therapeutics Reports Third Quarter 2024 Financial Res

BREAKING NEWS: $AXSM Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateTotal 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year ...more  
31
Post by whytestockson Sep 04, 2024 1:32pm

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmis

NEWS: $AXSM Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of MigraineNEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc ...more  
181
Post by whytestockson Jun 11, 2024 7:00pm

Buy Recommendation Issued On AXSM By Guggenheim

News; $AXSM Buy Recommendation Issued On AXSM By Guggenheim2024-06-11 16:30:03 ET Guggenheim analyst issues BUY recommendation for AXSM on June 11, 2024 03:28PM ET. The previous analyst recommendation ...more  
86
Post by whytestockson Feb 20, 2024 7:15pm

Neurology-Focused Axsome Therapeutics Reports Deeper Than Ex

NEWS: $AXSM Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones | BenzingaAxsome Therapeutics Inc@(NASDAQ:AXSM) reported fourth-quarter ...more  
74
Post by whytestockson Feb 20, 2024 7:00pm

Axsome Therapeutics Reports Fourth Quarter and Full Year 202

BREAKING NEWS: $AXSM Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateTotal 4Q and full year 2023 net product revenue of $71.5 million and ...more  
75
Post by AviseAnalyticson Jun 22, 2021 8:37am

5 MOST PROMISING ALZHEIMER’S DISEASE STOCK!

5 MOST PROMISING ALZHEIMER’S DISEASE STOCK! https://www.aviseanalytics.com/5-most-promising-alzheimers-disease-stock/
160
Comment by Marphineon Feb 12, 2021 7:35pm

RE:Awesome Run to Over $100 USD

Now 74$. First over 100 soon then?
142
Discussion
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities